Novaremed gets FDA nod for phase 2 trial of NRD135S.E1 for PDPN

This article was originally published here

The randomized, double-blind, placebo-controlled, multi-center study will have the primary objective of demonstrating the superiority of NRD135S.E1 over placebo in relieving PDPN in patients after 3 months of

The post Novaremed gets FDA nod for phase 2 trial of NRD135S.E1 for PDPN appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply